ABSTRACT E-selectin mediated cell-cell adhesion plays an important role in inflammatory processes and extravasation of tumor cells. Tumor necrosis factor-α (TNF-α) induces E-selectin gene and protein expression in primary human endothelial cells (HUVEC) and in an endothelial cell line (EA.hy-926). As shown by ELISA and FACS analyses, HMG-CoA reductase inhibitors (e.g., lovastatin) impair the TNF-α stimulated increase in E-selectin protein expression. Similar results were obtained for E-selectin mRNA expression and promoter activity, indicating that the effect of lovastatin is based on inhibition of gene expression. The effective inhibitory concentration of lovastatin was in a physiologically relevant range (IC 50 <0.1 µM). Lovastatin-mediated block of TNF-α induced E-selectin expression is due to inhibition of protein geranylgeranylation rather than farnesylation. Down-regulation of Rho signaling by coexpression of dominant-negative Rho mutants (i.e RhoA, RhoB and Rac) impaired TNF-α driven E-selectin gene expression, indicating Rho signaling to be essential for transcriptional activation of the E-selectin gene. Inhibition of E-selectin expression by lovastatin gives rise to a significant reduction in TNF-α stimulated adhesion of colon carcinoma cells to HUVEC. Furthermore, low concentration of lovastatin (i.e., ≤1 µM) attenuated TNF-α induced tumor cell invasion in vitro. The data support the view that statins might be clinically useful in protection against E-selectin mediated metastasis.
. Notably, E-selectin is also involved in the process of metastasis by promoting the adhesion of circulating tumor cells to the endothel (16) , which is a prerequisite for the extravasation step. A correlation between the expression of E-selectin and tumor specifically expressed E-selectin ligands (i.e., sialyl-LewisX or sialyl-LewisA) with the metastatic potential of malignant cells is best documented for colon carcinomas (17) (18) (19) (20) (21) (22) . Interestingly, the adhesion and the spreading of monocytes on endothelial cells are dependent on RhoA-regulated clustering of different types of cell adhesion receptors, including E-selectin (23) . Whether E-selectin promoted tumor cell adhesion is a further mechanism contributing to the metastatic potency of Rho proteins is unclear.
In view of the importance of E-selectin for metastasis, a promising therapeutical approach to counteract this process would be to inhibit E-selectin expression. E-selectin expression evoked by inflammatory cytokines such as tumor necrosis factor-α (TNF-α) requires the transcription factor NF-κB (24) (25) (26) (27) . Recently, we showed that the activation of stress-inducible signal mechanisms including NF-κB is attenuated by the HMG-CoA reductase inhibitor lovastatin (28, 29) . It is assumed that at least part of the inhibitory effect of statins on stress-induced signaling and gene expression is due to inhibition of the C-terminal isoprenylation of proteins belonging to the Ras/Rho family of small GTPases (28, (30) (31) (32) (33) . Furthermore, Rac/Cdc42-related signaling pathways were shown to potentiate E-selectin gene expression stimulated by TNF-α (34) . Whether Rho proteins are essential for the induction of E-selectin gene expression by TNF-α is still unclear. Overall, based on available data, it is tempting to speculate that statins might interfere with Rho-regulated expression of E-selectin. Studies that have analyzed the effect of statins on the basal level of soluble (i.e., shedded) E-selectin protein revealed inhibitory effects (35, 36) . In contrast, the effect of statins on E-selectin expression stimulated by TNF-α is still highly controversial. Data reported so far showed either potentiating or inhibitory effects (37) (38) (39) (40) . Unfortunately, none of these studies included E-selectin promoter analyses, which is clearly required to assess the influence of statins on cytokine-induced E-selectin gene expression.
The present study aimed at 1) characterizing the effect of statins on TNF-α induced E-selectin gene and protein expression, 2) answering the question of whether Rho signaling is essential for E-selectin gene induction, and 3) addressing the question of whether lovastatin is a suitable drug to impair TNF-α stimulated tumor cell adhesion and invasiveness in vitro.
MATERIALS AND METHODS

Materials
Lovastatin, simvastatin, geranylgeranyltransferase inhibitor type I (GGTI), and farnesyltransferase inhibitor (FTI) were purchased from Calbiochem (Bad Soden, Germany). Geranylgeranylpyrophosphate (GGPP), farnesylpyrophosphate (FPP), TNF-α, calcein AM, and oligonucleotides originate from Sigma (Sigma-Aldrich Chemie GmbH, Germany). Anti-E-selectin antibody used in this study was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and POD-conjugated anti-mouse antibody used for ELISA-analyses was obtained from Promega. FITC-conjugated anti-mouse antibody used for FACS-analysis was from Dako. The Titan One Tube RT-PCR Kit was from Roche Diagnostics GmbH. For cloning of the E-selectin promoter, PowerScript DNA Polymerase was used (PAN TM Biotech GmbH). Luciferase activity was determined by use of the Luciferase assay system (Promega). Rho expression vectors are described elswhere (41 were grown in Dulbecco's medium containing 10% heat inactivated fetal bovine serum (FBS). EA.hy-926 culture medium contains 1% HAT media supplement. HUVEC were cultured using the endothelial cell growth media system (EGM-2) from Clonetics (BioWhittaker) containing 2% fetal calf serum (FCS) according to the protocol of the manufacturer. HUVEC cells were used in the fourth to sixth passage for experiments.
ELISA analysis
For quantitation of E-selectin protein expression, an ELISA-based method was used. To this end, 4 x 10 4 endothelial cells were seeded into a 96-well microtiter plate and grown overnight. Medium was replaced before pretreatment and TNF-α stimulation of the cells. Four to five hours after addition of TNF-α, plates were incubated on ice for 10 min. Afterward, medium was removed and the cell layer was washed twice with ice-cold PBS/1% BSA. Cells were incubated with anti-E-selectin antibody for 90 min (1:50 in PBS/1%BSA). After being washed (3×), PODconjugated secondary antibody (1:1000 in PBS/1%BSA) was added for 60 min. All steps were performed on ice. Upon addition of p-nitrophenyl phosphate (pNPP) solution, enzymatic reaction was allowed to proceed for 30 min at room temperature before optical densitiy (E405 nm) was determined by ELISA plate reader. For calculation of specific binding of the E-selectin antibody, nonspecific binding of IgG 2a -isotype was subtracted (= ∆405 nm). At least three independent experiments (each performed in triplicate) were used for statistical interpretation of the data (means±SD).
FACS analysis
Four to five hours after TNF-α stimulation, cells were harvested using trypsin/EDTA and washed once with PBS before incubation with anti-E-selectin antibody (15 min, on ice). After being washed with PBS, FITC coupled secondary antibody was added and cells were further incubated for 15 min on ice. Afterwards, the level of E-selectin protein expression was quantified by FACS-analysis (FACScalibur; Becton-Dickinson). A total of 20,000 events was analyzed per sample to calculate the frequency of E-selectin positive cells and the mean level of E-selectin expression.
Determination of NO concentration
To measure NO production by iNOS or eNOS, the concentration of nitrite in the medium was determined using the Griess assay (42) and a chemiluminescence-based assay (Sievers NO Analyzer) (43) .
RNA expression analysis (RT-PCR)
Total RNA was isolated by use of a RNA Purification Kit (Sigma-Aldrich Chemie). One microgram of purified total RNA was used for RT-PCR analysis using the Titan One Tube RT-PCR System according to the protocol of the manufacturer (Roche Diagnostics). For PCR amplification, 25 cycles were performed (denaturation: 95°C, 1 min; annealing: 60°C, 2 min; polymerization: 68°C, 2 min). PCR products were separated onto agarose gels, and DNA was visualized by ethidium bromide staining. Primers for specific amplification of E-selectin mRNA were designed according to the E-selectin cDNA sequence published (NCBI Nucleotide GenBank; accession number: NM-000450; 5′-primer: 5′-TCTCTCAGCTCTCACTTTG-3′, 3′-primer: 5′-TTCTTCTTGCTGCACCTCT-3′). The E-selectin PCR product is 383 bp in length. Primers for amplification of GAPDH (392 bp PCR product) were as follows: 5′-primer: 5′-GTCTTCACCACCATGGAGAAGGCT-3′ and 3′-primer: 5′-CATGCCAGTGAGCTTCCCGTTCA-3′. Besides semiquantitative RT-PCR analysis, E-selectin mRNA expression was additionally quantitated by real-time PCR analysis (Bio-Rad, iCycler TM IQ) using SYBR Green as fluorescent dye.
Cloning of the E-selectin promoter and reporter gene analysis
Total genomic DNA was isolated from EA.hy-926 cells using the DNeasy TM -Tissue Kit (Qiagen GmbH). PCR primers for cloning of the human E-selectin promoter were designed according to the Eselectin gene sequence published previously (27) (5′-primer: 5′-AGGCTGGTCTTGAACTCCCG-3′; 3′-primer: 5′-GACTTCAAGAGTTCTTTTCACCC-3′). After amplification by touch down PCR (30 cycles) from 66°C down to 54°C, the resulting 1.24 kb E-selectin promoter fragment was cloned into XhoI/HindIII site of pGL3-Basic Vector (Promega). Succesful cloning of the E-selectin promoter was confirmed by sequencing. The sequence obtained was identical to that published previously (27) . To examine the transcriptional activation of the E-selectin promoter or of the NF-κB minimal promoter construct (3x NF-κB-luciferase), subconfluent HUVEC were transiently transfected with 2 µg of the corresponding construct. In the case of EA.hy-926 cells, transfection was done by use of the Effectene method (Qiagen), and transfection of HUVEC was performed using ESCORT TM III Transfection Reagent (Sigma-Aldrich). Eight hours after transfection, cells were pretreated or not with lovastatin and stimulated after a further incubation period of 16 h. Ten hours after TNF-α exposure, cells were harvested and luciferase activity was determined according to the protocol of the manufacturer (Promega). Determination of protein concentration of cell extracts was done by the method of Bradford (44) . Relative luciferase activity of treated cells was related to that of untreated control that was set to 1.
Analysis of cell adhesion
The adhesion of human colon carcinoma cells (DLD1) to a confluent monolayer of endothelial cells (HUVEC) was analyzed upon labeling of the tumor cells using the fluorescent dye calcein AM (excitation wavelength: 495 nm; emission at 517 nm). In more detail, colon carcinoma cells were labeled by incubation with 5 µM of calcein AM (Sigma-Aldrich) for 30 min at 37°C. Afterward, 5 x 10 5 of labeled tumor cells were added to a confluent cell layer of HUVEC, which had been stimulated or not for 5 h with TNF-α. Tumor cells were allowed to attach for 2 h at 37°C. Afterward, nonattached cells were removed by being washed with PBS (4x) and fluorescence was determined (Spectra MAX, Molecular Devices). Increase in tumor cell adhesion upon stimulation of HUVEC with TNF-α was calculated in relation to the basal adhesion of tumor cells to nonstimulated HUVEC that was set to 1.
Transmigration assay
As indication for tumor cell invasiveness, the transmigration of tumor cells through a monolayer of HUVEC was analyzed in vitro using 96-well Cell Invasion Chamber plates containing ECMatrix TM -coated inserts (Chemicon International, Inc.). HUVEC were seeded at high density into the coated inserts and were grown to confluency overnight. After pretreatment or not with lovastatin for further 24 h, medium was replaced and the endothelial cells were stimulated or not with TNF-α (1 ng/ml) for 3 h. Afterward, 3 x 10 5 metastatic colon carcinoma cells (HT-29 cells) were added. After overnight incubation, the number of transmigrated tumor cells was analyzed by DNA staining according to the protocol of the manufacturer. Basal migration of HT-29 cells through nonstimulated endothelial cell layer was taken as a control and set to 1.
RESULTS
Treatment of HUVEC with TNF-α results in a dose-dependent increase in E-selectin protein expression as shown by an ELISA assay (Fig. 1A) . Induction of E-selectin expression by TNF-α was confirmed by mRNA analysis (Fig. 1B) as well as by reporter gene analysis using a 1.24 kb human E-selectin promoter fragment that we have cloned from human endothelial cell line EA.hy-926 (Fig. 1C) . Sequence analysis proved the cloned E-selectin promoter to be identical to that described before (27) . The endothelial cell line EA.hy-926 also responded to TNF-α with a dose-dependent increase in E-selectin protein and gene expression (data not shown). Yet, an ~50-fold higher concentration of TNF-α was required to induce E-selectin expression in EA.hy-926 cells as compared with HUVEC (data not shown).
It is well established that NF-κB is crucial for E-selectin induction by TNF-α (24) . Recently, we reported that lovastatin, belonging to the group of clinically frequently used HMG-CoA reductase inhibitors, attenuates stress-induced activation of NF-κB (29) . Therefore, we examined the effect of HMG-CoA reductase inhibitors (i.e., lovastatin and simvastatin) on the expression of E-selectin by TNF-α in endothelial cells. As shown in Fig. 2A , both types of statins inhibit TNF-α stimulated E-selectin expression in a dose-dependent manner. Identical results were obtained using EA.hy-926 cells (data not shown). The ELISA-based data were confirmed by FACS analysis (Fig. 2B) . A large inhibition of E-selectin expression by lovastatin was also observed on the E-selectin mRNA level, as analyzed by semiquantitative RT-PCR analysis as well as by real-time PCR analysis using GAPDH as internal control (Fig. 2C) . The strong inhibitory effect of lovastatin on TNF-α stimulated E-selectin expression was confirmed on the level of the E-selectin promoter (Fig. 2D) . The inhibitory effect of lovastatin is independent of a decrease in the level of TNF receptor. ELISA and FACS-based analyses showed that the level of TNF-R1 was neither affected by TNF-α nor by lovastatin (data not shown). TNF-R2 expression was even slightly enhanced by TNF-α, which is in line with published data (45), as well as by lovastatin concentration ≥20 µM (our data, not shown). Furthermore, it should be noted that Eselectin expression induced by IL-1β (1 ng/ml) was also abrogated by lovastatin, although a higher lovastatin concentration was required (IC 50 ~50 µM). Overall, the data obtained clearly show that lovastatin is a powerful inhibitor of TNF-α stimulated E-selectin gene expression. Under these conditions, E-selectin protein induction is also abrogated.
In view of possible clinical relevance of the data obtained, it would be important to determine the lowest effective concentration of lovastatin that provokes E-selectin inhibition under the experimental condition that mimics the in vivo situation. Therefore, we examined whether a clinically relevant dose of lovastatin (i.e., ≤1 µM) impairs TNF-α induced E-selectin expression at a nonsaturating concentration of TNF-α in confluent HUVEC. As shown by FACS analysis, 10 pg/ml of TNF-α cause a strong increase in E-selectin protein expression (Fig. 3A) . Lovastatin treatment per se only slightly increased E-selectin expression (Fig. 3A) . Most important, 0.1−1 µM of lovastatin was sufficient to significantly (70-80%) reduce the level of TNF-α stimulated E-selectin expression (Fig. 3A and B) . The overall frequency of E-selectin positive cells observed after TNF-α stimulation was not affected by lovastatin (Fig. 3A) . Thus, lovastatin reduces the mean level of E-selectin expression in all TNF-α responding cells.
To characterize the type of isoprenylated protein(s) involved in the regulation of E-selectin gene expression upon TNF-α exposure in more detail, we investigated whether cotreatment with GGPP or FPP is able to revert the inhibitory effect of lovastatin. As shown in Fig. 4A , supplementation with GGPP significantly reverted inhibition of E-selectin expression by lovastatin whereas FPP did not. In line with this, GGTI but not FTI abrogated induction of Eselectin expression by TNF-α to a similar extent as lovastatin did (Fig. 4B) . Obviously, geranylgeranylated proteins are involved in the regulation of E-selectin expression by TNF-α.
Since Rho GTPases are reported as putative targets of statins (28, 30, 31) and contribute to NF-κB regulation (46) as well as to transcriptional activation of the E-selectin gene (34), we examined the effects of coexpression of dominant-negative Rho species on the activity of the Eselectin promoter. As shown in Fig. 4C , overexpression of dominant-negative forms of RhoA, RhoB, and Rac did not affect the basal level of E-selectin gene expression but largely inhibited TNF-α induced activation of the E-selectin promoter (Fig. 4C) . Based on this, we suggest that RhoA-, RhoB-, and Rac-dependent signal mechanisms are essential for TNF-α mediated induction of the E-selectin gene.
Since E-selectin plays an important role in the attachment of tumor cells to the endothelium during the process of metastasis (16), the question arises as to whether pharmacological inhibition of E-selectin expression by lovastatin reduces tumor cell adhesion. As shown in Fig.  5A , TNF-α caused a dose-dependent increase in the adhesion of human colon carcinoma cells (DLD1) to a confluent layer of endothelial cells (i.e., HUVEC). Already at concentration as low as 0.1-1 µM, lovastatin significantly blocked cytokine-induced adhesion by 50-60% (Fig. 5B and  C) . At this concentration, lovastatin itself exerted no significant effect on tumor cell adhesion (Fig. 5B) . Inhibition of TNF-α triggered tumor cell adhesion is additionally illustrated by the microscopical analysis shown in Fig. 5C . Expression of P-selectin, which was shown to be inducible by TNF-α in murine endothelial cells (47, 48) , was not stimulated under our treatment conditions in HUVEC (Fig. 5D ). This is in line with another report (49) . Furthermore, a low dose of lovastatin did not affect TNF-α stimulated expression of the adhesion molecule ICAM-1 (Fig.  5D ). ICAM-1 expression was inhibited only when high concentration of lovastatin was used (IC 50 ~70 µM) (data not shown). This shows that the inhibitory effect of lovastatin as observed in our experiments is pretty specific for E-selectin. Interestingly, the level of reduction of tumor cell adhesion (Fig. 5B) quantitatively correlates with the level of E-selectin inhibition (Fig. 5D ). This finding, together with the inability of low concentration of lovastatin to block ICAM-1 induction, strongly supports the conclusion that attenuation of TNF-α induced E-selectin expression is a main underlying mechanism for the observed inhibition of tumor cell adhesion by lovastatin. To check whether lovastatin affects a downstream event of tumor cell adhesion, namely invasiveness, we analyzed the transmigration of metastatic colon carcinoma cells through a confluent monolayer of HUVEC. As shown in Fig. 6 , already 0.1-1 µM of lovastatin drastically reduced tumor cell invasion in vitro. It might be speculated that the signaling molecule NO is involved in these processes. Yet, TNF-α and lovastatin did not cause any changes in NO production under our experimental conditions, as measured by use of Siever's NO Analyzer and the Griess assay (data not shown). Therefore, the observed effects of lovastatin on cell adhesion and invasion are independent from NO-triggered pathways.
DISCUSSION
Modulation of expression of the cell adhesion molecule E-selectin can be considered as a promising strategy for improving inflammatory and tumor therapy. Here, we addressed the questions of the regulation and pharmacological modulation of E-selectin gene and protein expression upon stimulation of endothelial cells with TNF-α. This cytokine increases E-selectin gene and protein expression in primary HUVEC as well as in the endothelial cell line EA.hy-926 (data not shown). Mutational inactivation of the NF-κB binding site in the promoter of the Eselectin gene or expression of dominant-negative IκBα abrogates E-selectin induction, showing NF-κB to be essentially required (24, 50, 51) . Recently, we found that activation of NF-κB by different types of stress, including TNF-α, is blocked by the HMG-CoA reductase inhibitor lovastatin (28, 29) . This observation prompted us to investigate whether lovastatin is a pharmacological useful tool to modulate E-selectin expression. We observed that lovastatin largely attenuates E-selectin gene and protein expression induced by TNF-α. The inhibitory effect of lovastatin was observed in both HUVEC and EA.hy-926 cells (data not shown). So far, data reported regarding the effect of statins on E-selectin expression after TNF-α stimulation of endothelial cells are rather contradictory. Thus, both stimulatory (40) and inhibitory (37) effects of statins were described, with E-selectin mRNA levels being either enhanced (38) or reduced (39) . Therefore, both transcriptional and posttranscriptional mechanisms have been suggested to underly the effect of statins. The reason for these inconsistent observations is unclear. It is important to note, however, that the effect of statins on TNF-α induced E-selectin expression has not yet been analyzed on the level of the E-selectin promoter. Therefore, up to now it was not possible to draw an experimental verified conclusion as to the effect of statins on TNF-α induced expression of the E-selectin gene. We included FACS-and ELISA-based protein, mRNA and promoter analyses in our study, providing evidence that lovastatin abrogates TNF-α stimulated E-selectin gene and protein expression in HUVEC. Furthermore, our findings show that inhibition of gene expression is the major mechanism of lovastatin that causes a reduction in TNF-α induced E-selectin protein expression. The inhibitory effect of lovastatin is not due to loss of the TNF receptor. Neither TNF-R1 nor TNF-R2 expression was reduced by lovastatin. At a lovastatin concentration ≥20 µM, TNF-R2 expression was even enhanced. Specific upregulation of TNF-R2 expression was also observed upon stimulation of HUVEC with TNF-α, which is in line with reported data (45) . Also, IL-1β induced expression of E-selectin was attenuated by lovastatin, yet to a lower extent than its induction by TNF-α. This might be due to the fact that different types of lovastatin target molecules (i.e., Rho GTPases or others) are involved in either TNF or IL-1 receptor triggered signaling to NF-κB.
Since cotreatment with GGPP but not FPP reverted the inhibitory effect of lovastatin and specifically GGTI attenuated E-selectin induction by TNF-α, we suggest that predominantly geranylgeranylated proteins are involved in the regulation of E-selectin expression. Isoprenylated regulatory proteins that are inhibited by statins are Ras and Rho GTPases (28-31, 33) . Furthermore, overexpression of Rac or Cdc42 potentiated TNF-α driven E-selectin expression (34) . Bearing this in mind, we speculated that inhibition of Rho/Rac signaling by lovastatin is responsible for inhibition of E-selectin induction. This hypothesis gains support by the observation that coexpression of dominant-negative RhoA, RhoB, and Rac abrogated transcriptional activation of the E-selectin promoter by TNF-α. Obviously, Rho/Rac signaling is essential for stimulation of E-selectin gene expression by TNF-α. Previously it was shown that inactivation of RhoA-like GTPases (i.e., RhoA, RhoB, RhoC) by Cl. botulinum toxin C3 inhibited clustering of cell adhesion receptors, including E-selectin, on the cell surface (23) . In contrast to RhoA-like proteins, Rac and Cdc42 do not participate in the regulation of receptor clustering (23) . Taking these reports and our data together, it appears that Rho GTPases play a central role in the regulation of E-selectin function by affecting both gene expression and receptor clustering. Under conditions of blockage of TNF-α stimulated E-selectin gene expression by lovastatin, E-selectin protein induction is also abrogated. Therefore, an inhibitory effect of the statin on Rho-regulated receptor clustering, which basically cannot be ruled out, is not longer relevant.
An important aspect of our study is that pharmacological inhibition of E-selectin expression by lovastatin was observed at a low concentration, pointing to the clinical impact of the findings. If nongrowing HUVEC were stimulated with a low dose of TNF-α, the lovastatin concentration inhibiting the expression of E-selectin by 50% (ID 50 ) was <100 nM. This concentration is in the range of what is achieved in patients on the basis of an oral intake of ~100 mg per day. In view of a possible clinical relevance of the data, we addressed the question of whether lovastatin may influence tumor cell adhesion to the endothel. Indeed, we observed that TNF-α induced increase in the adhesion of human colon carcinoma cells to endothelial cells was clearly attenuated by lovastatin at physiologically relevant dose of 0.1-1.0 µM. Noteworthy, lovastatin-mediated reduction in tumor cell adhesion was accompanied by a quantitatively similar decrease in the level of E-selectin protein expression. Within the same experimental setting, TNF-α stimulated expression of ICAM-1 was not affected by lovastatin. A similar observation was made by others (52) . TNF-α induced expression of ICAM-1 was only affected at high concentration of lovastatin (i.e., ≥50 µM), indicating that the physiological relevance of NF-κB in the context of the complete promoters of either E-selectin or ICAM-1 is different. Another factor known to affect cellular adhesion is NO. Regarding leukocytes, NO affects cell adhesion in a negative manner (53) . With respect to the effect of NO on tumor cell adhesion, contradictory data are reported (54, 55) .
As known from the literature, TNF-α alone stimulates neither human iNOS (56, 57) nor human eNOS expression (58) . Furthermore, when we analyzed the effect of TNF-α and lovastatin on NO production in HUVEC using two different methods [i.e., Griess assay (42) and chemiluminescence-based NO analysis (43) ], no significant changes in NO production could be detected (data not shown). This shows that NO does not interfere with the observed effects of TNF-α and lovastatin on tumor cell adhesion. Thus, altogether, our findings indicate that inhibition of Rho-regulated E-selectin expression is of particular relevance for lovastatinmediated attenuation of tumor cell adhesion, at least if a low dose of lovastatin is used. Eselectin-mediated adhesion of tumor cells to the endothelium is considered to promote extravasation of tumor cells (16) . In line with this, we found that low concentrations of lovastatin (i.e., 0.1-1 µM) largely abrogated TNF-α stimulated transmigration of metastatic colon carcinoma cells through a monolayer of HUVEC. Lovastatin-mediated inhibition of other Rhoregulated mechanisms, in particular of cell motility, has also been shown to reduce tumor cell invasion in vitro (59) (60) (61) . In the latter studies, tumor cells were exposed to statins, whereas in our experimental system only the endothelial cells have been pretreated with lovastatin. Obviously, lovastatin can counteract metastatic processes both on the level of the tumor cells and the endothelial cells. In total, our data support the hypothesis that statins might be useful as antimetastatic drugs (59, 62) , in particular under conditions of increased TNF-α production, e.g., during inflammation, which is often observed in large necrotic tumors.
The role of Rho proteins in invasion and metastasis is well established (9, 10, 12) , although mechanistically not completely understood. The data presented here indicate that E-selectinmediated adhesion of tumor cells to the endothel contributes to the prometastatic potency of Rho proteins. This metastasis-promoting effect becomes attenuated by lovastatin (Fig. 7) . Since HMG-CoA reductase inhibitors are well established and frequently used pharmaceuticals, our finding of inhibition of cytokine-induced E-selectin expression, tumor cell adhesion and invasion by lovastatin might have important clinical impact. Thus, it would be an interesting focus of forthcoming studies, involving animal models and clinical trials, to see whether intake of statins affects tumor cell metastazation. 
Figure. 1 TNF-α increases E-selectin protein and gene expression in human endothelial cells (HUVEC). A)
Subconfluent HUVEC were treated with different concentrations of TNF-α as indicated. E-selectin protein expression was analyzed 5 h later by ELISA assay. B) Analysis of E-selectin mRNA expression was performed 3 h after TNF-α treatment by RT-PCR. The inverse graph of the ethidium bromide stained gel is shown. mRNA expression of GAPDH is included as a control. E-sel, E-selectin cDNA used as a positive control for PCR reaction. C) To investigate the expression of Eselectin on the level of the promoter, HUVEC were transfected with E-selectin promotor luciferase construct. Twenty-four hours after transfection, cells were treated with TNF-α (1 ng/ml). A further 8 h later, cells were harvested for determination of luciferase activity, which was set to 1 in the untreated control. Data shown in A and C are means ± SD from at least 3 independent experiments, each performed in duplicate. were pretreated or not overnight with different concentrations of lovastatin or simvastatin. Afterward, TNF-α (1 ng/ml) was added, and a further 5 h later, E-selectin protein expression was analyzed by ELISA-based method (A) or by FACS analysis (B). Data are means ± SD from at least 3 independent experiments. C) Upon pretreatment of HUVEC with lovastatin (20 µM, overnight), cells were exposed to TNF-α (1 ng/ml). Three hours later, cells were harvested for analysis of E-selectin mRNA expression by RT-PCR analysis. mRNA expression of GAPDH is included as a control. Shown is the ethidium bromide stained gel (inverse presentation) derived from semiquantitative RT-PCR. The quantitation shown below the autoradiogram is based on real time PCR analysis. D) 24 h after transfection of HUVEC with E-selectin promoter luciferase construct cells were pretreated or not overnight with lovastatin (20 µM) before TNF-α stimulation (1 ng/ml). Cells were harvested for determination of luciferase activity 8 h later. Data are means ± SD from 3 independent experiments each performed in duplicate. . Afterward, cells were stimulated with TNF-α (100 ng/ml), and after a further incubation period of 5 h, E-selectin protein expression was analyzed by ELISA. Data are means ± SD from 3 independent experiments each performed in triplicate. B) Endothelial cells (EA.hy-926) that have been pretreated or not (Con) for 72 h with farnesyltransferase inhibitor (FTI, 50 µM) and geranylgeranyltransferase type I inhibitor (GGTI, 50 µM) were stimulated with TNF-α (100 ng/ml). Five hours later E-selectin expression was determined by ELISA assay. Data are means ± SD from 3 independent experiments each performed in triplicate. C) HUVEC were transfected with E-selectin promoter luciferase construct together or without expression constructs coding for the dominant-negative RhoA (dnRhoA), RhoB (dnRhoB), or Rac1 (dnRac). After overnight incubation, cells were treated with TNF-α (1 ng/ml). After further incubation period of 8 h, cells were harvested for determination of luciferase activity. Relative luciferase activity in untreated control was set to 1. Data are means ± SD from at least 2 independent experiments each performed in duplicate. Con, not transfected with dnRho mutants. 5 of calcein-labeled human colon carcinoma cells (DLD1) were added and adhesion of DLD1 cells was quantitated as described in Materials and Methods. Data are means ± SD from 3 independent experiments performed in quadruplicate. B) Confluent HUVEC were pretreated or not for 24 h with the indicated doses of lovastatin (0.1-20 µM). Afterward, cells were exposed to TNF-α (1 ng/ml). After a further incubation period of 5 h, adhesion of calcein-labeled human tumor cells (DLD1) was assayed as described in Materials and Methods. Data are means ± SD from at least 2 independent experiments, each performed in quadruplicate. Identical results were obtained with lower concentration of TNF-α (10 pg/ml and 100 pg/ml) (data not shown). C) Illustration of the inhibitory effect of lovastatin (1.0 µM, overnight) on TNF-α (1 ng/ml)induced adhesion of colon carcinoma cells (DLD1) to HUVEC. a, nonstimulated HUVEC + DLD1; b, lovastatin pretreated HUVEC + DLD1; c, TNF-α -stimulated HUVEC + DLD1; d, lovastatin pretreated TNF-α-stimulated HUVEC + DLD1. D) Confluent human endothelial cells (HUVEC) were pretreated or not for 24 h with 0.1 µM or 1.0 µM of lovastatin. Five hours after TNF-α exposure, expression of E-selectin, P-selectin, and ICAM-1 was analyzed by ELISAbased method. Data are means ± SD from 3 independent experiments each performed in triplicate. Statins decrease the intracellular concentration of isopren precursor moieties that are required for C-terminal isoprenylation of Rho proteins by corresponding isopren transferases (i.e., geranylgeranyl-or farnesyl-transferase). Because C-terminal isoprenylation is essential for correct intracellular localization and function of Rho GTPases, statins can impair their activity. Thus, via inhibiting Rho-dependent activation of NF-κB, statins attenuate TNF-α-induced Eselectin gene expression and thus also E-selectin protein induction. Under conditions of blockage of E-selectin protein expression, a putative inhibitory effect of lovastatin on receptor clustering is no longer relevant. Since E-selectin acts as a ligand for tumor specific expressed Sialyl-LewisX and Sialyl-LewisA glycoproteins, it promotes the adhesion of tumor cells to the endothel. By blocking TNF-α induced Rho-dependent E-selectin expression, lovastatin causes inhibition of the adhesion of tumor cells to endothelial cells.
